Peru Pharmaceuticals & Healthcare Report Q1 2015
Headline Expenditure Projections
Risk/Reward Index : In BMI's Risk/Reward Index for Q1 2015, Peru remains 10th out of the 18 markets surveyed in the Americas matrix. Peru's Reward and Risk scores are both viewed as less favourable than the regional averages. A small market size and a deficient intellectual property environment are some of the major drawbacks to the involvement of foreign companies in Peru. Nevertheless, Peru is still seen as being able to offer longer-term benefits to foreign investors, on account of the expected healthcare market development and economic growth.
- Pharmaceuticals: PEN4.38bn (USD1.62bn) in 2013 to PEN4.66bn (USD1.64bn) in 2014; +6.6% in local currency terms and +4.0% in US dollar terms. H istoric market size revised upward while projected growth rate revised down from Q414.
- Healthcare: PEN29.13bn (USD10.78bn) in 2013 to PEN31.84bn (USD11.21bn) in 2014 +9.3% in local currency terms and +4.0% in US dollar terms. Historic market size and projected growth rates are revised upward from Q414.
Key Trends And Developments
The Peru Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.
- In November 2014, Peruvian national health insurance company, EsSalud, announced its plan to contract 1,000 new healthcare staff throughout 31 health facilities after receiving criticism of understaffed hospitals and health facilities throughout the country.
- In October 2014, Peru's Health Ministry announced the country's commitment to the prevention of Ebola through professional training and increased public awareness.
- In September 2014, EsSalud announced its plans to build three...
BMI's Peru Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Peruvian pharmaceutical and healthcare industry.
- Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Peru to test other views - a key input for successful budgeting and strategic business planning in the Peruvian pharmaceutical and healthcare market.
- Target business opportunities and risks in the Peruvian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Peru.
- Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.
BMI Industry View & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.
Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.
Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.
BMI Industry Forecasts
Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)
Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)
Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)
Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)
OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)
Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)
Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.
Strict quality controls for imported medicines, multiple trade agreements with the US and EU, and favourable business and investor environments will allow Peru to continue developing and benefiting from pharmaceutical investments. Steady increases in the growth of the Peruvian pharmaceutical market and a commitment to healthcare improvements will generate revenue opportunities for multinational investors.
BMI Industry View
Pharmaceutical Market Forecast
Table: Pharmaceutical Sales, Historical Data And Forecasts (Peru 2010-2018)
Healthcare Market Forecast
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Peru 2010-2018)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Peru 2010-2018)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Peru 2010-2018)
Prescription Drug Market Forecast
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Peru 2010-2018)
Patented Drug Market Forecast
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Peru 2010-2018)
Generic Drug Market Forecast
Table: Generics Drug Market Indicators, Historical Data And Forecasts (Peru 2010-2018)
OTC Medicine Market Forecast
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Peru 2010-2018)
Pharmaceutical Trade Forecast
Table: Pharmaceutical Trade Data And Forecasts (Peru 2012-2018)
Table: Pharmaceutical Trade Data And Forecasts local currency (Peru 2012-2018)
Other Healthcare Data
Key Risks To BMI's Forecast Scenario
Table: Peru - Economic Activity
Industry Risk Reward Ratings
Americas Risk/Reward Ratings
Peru Risk/Reward Ratings
Industry Trends And Developments
Table: Selected Causes of Death by Sex, 2010
Table: MINSA's Decentralised Institutions & Institutes, 2011
Healthcare Sector Developments
Table: Infrastructure, 2004-2009
Table: Key Goals of Parsalud II In Nine Regions
Research and Development (R&D)
Recent Regulatory Developments
Intellectual Property Regime
Table: Peruvian Watchdog of Pharmaceutical Products (Observatorio Peruano de Productos Farmac-uticos, OPPF)
Pricing And Reimbursement Developments
Table: Price Components Of Two Imported Medicines In Both Private And Public Sectors
Table: Public Procurement of Pharmaceuticals by Provider, 2007-2009 (PENmn)
Table: Peruvian Pharmaceutical Companies That Acquired GMP Accreditation In 2006
Table: Members of ADIFAN, 2011
Recent Pharmaceutical Sector Developments
Merck & Co
Teva (Corporaci-n Medco)
Table: Peru's Population By Age Group, 1990-2020 ('000)
Table: Peru's Population By Age Group, 1990-2020 (% of total)
Table: Peru's Key Population Ratios, 1990-2020
Table: Peru's Rural/Urban Population, 1990-2020
Pharmaceutical Expenditure Forecast Model
Healthcare Expenditure Forecast Model
Notes On Methodology
Risk/Reward Ratings Methodology
Table: Pharmaceutical Risk/Reward Ratings Indicators
This report does not have a list of Companies Mentioned available
This report does not have a press release associated with it